Ventyx Biosciences Inc (VTYX)
4.805
-0.18
(-3.51%)
USD |
NASDAQ |
May 20, 16:00
4.805
0.00 (0.00%)
After-Hours: 17:41
Ventyx Biosciences Cash from Financing (TTM): 100.87M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 100.87M |
| December 31, 2023 | 53.33M |
| September 30, 2023 | 42.39M |
| June 30, 2023 | 218.56M |
| March 31, 2023 | 216.33M |
| Date | Value |
|---|---|
| December 31, 2022 | 167.77M |
| September 30, 2022 | 337.71M |
| June 30, 2022 | 210.30M |
| March 31, 2022 | 266.77M |
| December 31, 2021 | 323.55M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
42.39M
Minimum
Sep 2023
337.71M
Maximum
Sep 2022
193.76M
Average
213.31M
Median
Cash from Financing (TTM) Benchmarks
| Anavex Life Sciences Corp | 18.40M |
| CERo Therapeutics Holdings Inc | -- |
| Avinger Inc | 5.112M |
| Checkpoint Therapeutics Inc | 46.43M |
| RAPT Therapeutics Inc | 10.37M |